You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Developing a Nutraceutical Product against Ototoxicity
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIDCDPROJECT SUMMARYDespite recent advances in cancer therapiesplatinum based drugs are still widely used for the treatment of solid tumorsA primary example is cisplatinwhich is frequently used to treat lungbladdertesticularand cervical cancersHoweverlimitations of this therapy include the development of drug resistance in cancer cells as well as severe side effectssuch as nephrotoxicity and neurotoxic ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Rapid high-resolution typing of Human Leukocyte Antigen genes by nanopore sequencing for transplantation
SBC: NEWVENTUREIQ LLC Topic: NIAIDABSTRACT Human leukocyte antigenHLAtyping is an essential laboratory test to evaluate the donor recipient compatibility before life saving transplantationsInaloneHLA typing of donors and recipients guided overorgan and stem cell transplantations in the United StatesExisting high resolution HLA typing methods require a turnaround time of days to weeksThere has been an unmet clinical need for a rapi ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Biologically Targeted Vaccine for Chikungunya
SBC: PRECISION VIROLOGICS INC Topic: NIAIDPROJECT SUMMARY ABSTRACT Chikungunya virusCHIKVis a mosquito transmitted alphavirus that causes explosive epidemics of a severe febrile illness characterized by debilitating polyarthralgia in humansCHIKV caused an estimatedmillion new cases in India alone inand has the potential to spread globally because of the distribution and abundance of its mosquito vectorsAedes aegypti and Aedes albopictusDu ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a Novel Bio-Adhesive Mesh System for Abdominal Hernia Repair
SBC: CIRCA BIOSCIENCE LLC Topic: 300Development of a Novel Bio Adhesive Mesh System for Abdominal Hernia Repair Project Summary Abstract This project proposes the development of a novel mesh adhesive system for abdominal hernia repair utilizing surface modification of polymer surgical mesh to allow for improved tissue fixation with a poloxamine hydrogel adhesiveMore thanmillion Americans undergo hernia repair with surgical mesh each ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Developing and validating a podocyte cell-based diagnostic assay for identifying recurrent focal and segmental glomerulosclerosis patients
SBC: InDepth Pharmaceuticals, LLC Topic: 400Diagnosing glomerular diseases accurately and in timely fashion is key to developing a successful treatment plan and thereby prevent their progression to ESRDend stage renal diseaseHowevertheir successful diagnosis remains challenging due to the complex diagnostic procedures used including invasive renal biopsiesThusthere is a compelling need to develop simplified procedures to detect glomerular d ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a bioconjugate vaccine against Group B Streptococcus
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Streptococcus agalactiae, commonly referred to as Group B Streptococcus (GBS), is a leading cause of neonatal meningitis and sepsis worldwide as well as an agent of invasive disease in both pregnant and non-pregnant adults. GBS neonatal disease manifests as early onset, defined as disease within the first six days after birth, or late onset, defined as disease occurring after the f ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Novel antibacterial agents derived from natural products
SBC: Promiliad Biopharma Incorporated Topic: NIAIDSPECIFIC AIMSAntibiotic resistance among common bacterial pathogens is a serious public health problem as it compromises our ability to treat infectious disease. The resistance problem is compounded by the relative lack of discovery of new antibiotics, especially those with novel mechanisms of action. New antibiotics are critically needed as resistance to recently developed antibiotics is growing. ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Use of mimotope vaccine technology to develop vaccines against bacterial pathogens
SBC: ZenVax LLC Topic: NIAIDABSTRACT This Small Business Technology TransferSTTRPhase I proposal is in response toNIH NIAID Research Topics in Division of Microbiology and Infectious Diseases and Bacteriology and Mycology BranchVaccine for prevention of human Q feverQ fever is a worldwide zoonotic disease that is caused by the obligate intracellular Gram negative bacteriumCoxiella burnetiiThe highly infectious nature of Cbur ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
MITOFUSIN AGONISTS TO TREAT NEURODEGENERATIVE DISEASE
SBC: Mitochondria in Motion, Inc. Topic: 999Mitofusin agonists for the treatment of neurodegenerative diseases Gerald W Dorn II, MD Mitochondria in Motion, Inc. Washington University in St Louis School of Medicine Abstract: There are a number of rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease (HD), for which there is no available or effective therapy and which lead to significant mor ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Design and Development of Targeted-Liposome for drug delivery to lung cancer by exploiting a vulnerability induced by radiotherapy
SBC: Medical Guidance Systems LLC Topic: 102Abstract The proposed drug development will result in the design and development of a ligand targeted liposomeLTLthat will aid in the targeted delivery of therapeutics to patients with Non Small Cell Lung CancerNSCLCWe propose an innovative active targeting strategy and our technology exploits the stress response that occurs within the cancer cells following exposure to ionizing radiationThis lipo ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health